BridgeBio secures USD 1b to scale Attruby launch and fund three incoming programs

Palo Alto-based BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced a USD 1 billion private placement of Series A Cumulative Convertible Participating Preferred Stock, with proceeds directed at funding the commercial scaling of acoramidis (Attruby) and financing pre-launch activities for three additional late-stage programs expected to reach the US market within the next 12 months. The transaction reflects investor confidence in BridgeBio's near-term commercial trajectory at a moment when the company carries substantial debt and faces compounding pre-commercial expenditures.

Sixth Street led the BridgeBio funding round with an USD 800 million commitment, while HealthCare Royalty, a business of KKR (NYSE: KKR), contributed USD 133.9 million at close, bringing total funded proceeds to USD 933.9 million against the USD 1 billion facility. The preferred shares carry a 7% dividend and are initially convertible at USD 137.79 per share, more than double BridgeBio's recent trading price, limiting immediate dilution. Unlike many preferred financings, the securities have no maturity date or holder redemption rights, reducing refinancing pressure. HealthCare Royalty's participation is notable given its existing relationship with BridgeBio: the two parties completed a USD 300 million royalty monetization of BridgeBio's European acoramidis royalty stream in June 2025, deepening a capital partnership that now spans two distinct financing structures.

Acoramidis (Attruby), approved by the US FDA in November 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), generated USD 180.6 million in US net product revenue in Q1 2026 alone, with total Q1 revenues of USD 194.5 million across product sales, royalties, and licensing. Despite that commercial momentum, BridgeBio reported a net loss of USD 164 million for the quarter, reflecting the cost burden of commercializing Attruby while simultaneously building pre-commercial infrastructure for three additional programs. Cash and marketable securities stood at USD 940.2 million as of March 31, 2026, prior to this financing. The USD 1 billion raise substantially extends financial flexibility as the company prepares for what management has described as three critical launches over the next 12 months.

The three near-term programs are BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), encaleret for autosomal dominant hypocalcemia type 1 (ADH1), and infigratinib for achondroplasia. BridgeBio submitted the New Drug Application for BBP-418 to the FDA in March 2026, with a US launch anticipated in late 2026 or early 2027 pending approval. The NDA for encaleret is targeted for submission in H1 2026, with a US launch expected in early 2027. Infigratinib's NDA submission is planned for Q3 2026, with a US launch targeted for early to mid 2027. All three programs have received Breakthrough Therapy Designation or equivalent priority review designations from the FDA, and all three may be eligible for Priority Review, which would compress standard review timelines. The positive Phase III topline results for infigratinib in achondroplasia, reported in February 2026, demonstrated statistically significant improvements in annualized height velocity and, in a pre-specified exploratory analysis, the first statistically significant improvement in body proportionality against placebo reported for any therapy in the indication.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

---

Spot something wrong? Report an issue with this article